MethylGene Inc. (TSX: MYG) is a clinical-stage biopharmaceutical company that develops novel therapeutics for cancer and infectious disease. The Company’s lead product candidates include: MGCD265, an oral Met/VEGFR kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers and MGCD290, a fungal Hos2 inhibitor, for use in combination with fluconazole for fungal infections, which has completed Phase 1 clinical studies. The Company’s partners include Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc.
About MGCD265
MGCD265 is a novel, orally active small molecule inhibitor that targets a unique spectrum of receptor tyrosine kinases: Met, VEGFR 1, 2, and 3, Tie-2 and Ron. These kinases play key roles in tumor development, survival and metastasis as well as the inappropriate formation of blood vessels (angiogenesis) that nourish the tumor. MGCD265 is nearing completion of two Phase 1 single agent clinical trials and one Phase 1/2 combination clinical trial (with erlotinib and docetaxel) in solid tumors.
Company Details
- Founded
- -
- Phone
- 514.337.3333
- in****@****ene.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- methylgene.com
- Keywords
- Mississauga.
Methylgene Inc. Questions
Methylgene Inc.'s helpline number is 514.337.3333
Methylgene Inc.'s website is methylgene.com
Methylgene Inc.'s LinkedIn profile is https://www.linkedin.com/company/methylgene-inc.
Methylgene Inc.'s industry is
Biotechnology Research
Methylgene Inc.'s top competitors are
Bryoptera Clinical Services,
Liminal Biosciences,
Paraza Pharma Inc.,
Laboratoires Chemrf Inc. / Chemrf Laboratories Inc.,
Chemrf Laboratories Inc.,
Maxxam Analytics,
Caledon Bioscience Inc.,
Cyclenium Pharma Inc.,
Bruker Daltonics,
Valens Labs.
Methylgene Inc.'s support email address is info@methylgene.com
Methylgene Inc.'s categories are Biotechnology Research
Methylgene Inc.'s founding year is 1997
